FDA Concerned With Side Effect of Oscient Drug

Law360, New York (September 11, 2006, 12:00 AM EDT) -- Armed with studies showing a high risk of skin rashes from Oscient Pharmaceuticals Corp.’s Factive antibiotic, regulators at the FDA have planned a meeting on the safety and efficacy of the sinusitis drug for Tuesday.

Oscient is seeking FDA approval for a five-day version of the drug meant to treat acute sinus infections. The leading ingredient in Factive, gemifloxacin, is already approved as a seven-day treatment for community-acquired pneumonia and a five-day treatment for certain cases of chronic bronchitis.

Sinusitis is an inflammation of the sinuses...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.